EpilepsyGTx and Viralgen have announced a partnership to advance production of EPY201, EpilepsyGTx’s lead investigational ...

GSK has announced that Japan’s Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of ...

Zerion Pharma has announced that one of its partners has submitted a marketing authorisation application in several European countries for a medicinal product formulated with the company’s Dispersome ...

New phase 3 data presented at ERS 2026 and published in the New England Journal of Medicine indicate that tozorakimab could reshape biologic treatment in COPD, delivering clinically meaningful ...

EGFR Ex20ins mutations account for around 12% of all EGFR mutations. These patients have historically faced poorer outcomes ...

NICE also endorsed an MRD‑guided approach, allowing daratumumab to be stopped after at least 24 months of maintenance if MRD remains negative for at least 12 months. Scott Purdon, Head of Patient ...

TT‑P34 is designed to improve both mitochondrial and lysosomal function, targeting a pathway implicated in multiple ...

Clinical research is entering a new era: advances in methodological approaches, the growing integration of real-world ...

Lucid Group has announced that Eric Muller has joined the agency as Chief Executive Officer. He succeeds CEO and original DiD ...

There is currently no cure for PBC, with treatment aiming to manage symptoms, improve quality of life and slow disease ...

CSL Seqirus has announced publication of pivotal phase 3 results for its MF59‑adjuvanted cell‑based higher‑dose quadrivalent influenza vaccine in The Lancet Infectious Diseases, marking what the ...

Pace has appointed Andrew Fenny as President of Pace Life Sciences to lead the division into its next phase of strategic ...